An EphA2 tyrosine kinase inhibitor has been shown to induce tumour regression in human non-small cell lung cancer (NSCLC) xenografts in vivo, indicating that EphA2 is a promising molecular target in cancer therapy8. Here, EPHA2 is linked to non-small cell lung carcinoma.